Adverse pregnancy outcomes after abnormal first-trimester screening for aneuploidy

Clinics in Laboratory Medicine

Volumn 30, Issue 3, 2010, Pages 613-628

  Goetzl, Laura ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Congenital heart disease; First trimester screening; Intrauterine fetal demise; Intrauterine growth restriction

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; INHIBIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADVERSE OUTCOME; ANEUPLOIDY; BLOOD ANALYSIS; CONGENITAL HEART MALFORMATION; DIAGNOSTIC VALUE; FETUS DEATH; FETUS ECHOGRAPHY; FETUS MALFORMATION; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; INTRAUTERINE INFECTION; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPONTANEOUS ABORTION; BLOOD; CONGENITAL ABNORMALITIES; FEMALE; GENETICS; MASS SCREENING; PREDICTIVE VALUE; PREGNANCY;

ANEUPLOIDY; CONGENITAL ABNORMALITIES; FEMALE; HUMANS; MASS SCREENING; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST;

EID: 77954800892     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2010.04.003     Document Type: Review

References (99)

1. Souka A.P., Snijders R.J.M., Novakov A., et al. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1998, 11:391-400.
2. Souka A.P., Krampl E., Bakalis S., et al. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 2001, 18:9-17.
3. Michailidis G.D., Economides D.L. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 2001, 17:102-105.
4. Souka A.P., von Kaisenberg C.S., Hyett J.A., et al. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005, 192:1005-1021.
5. Hyett J.A., Perdu M., Sharland G.K., et al. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol 1997, 10:242-246.
6. Hyett J., Perdu M., Sharland G., et al. Using fetal nuchal translucency to screen for major congenital heart defects at 10-14 weeks gestation: population based cohort study. BMJ 1999, 318:81-85.
7. Ghi T., Huggon I.C., Zosmer N., et al. Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound Obstet Gynecol 2001, 18:610-614.
8. Aztei A., Gajewska K., Huggon I.C., et al. Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 2005, 26:154-157.
9. Simpson L.L., Malone F.D., Bianchi D.W., et al. Nuchal translucency and the risk of congenital heart disease. Obstet Gynecol 2007, 109:376-383.
10. Clur S.A., Mathijsssen I.B., Pajkrt E., et al. Structural heart defects associated with an increased nuchal translucency: 9 years experience in a referral center. Prenat Diagn 2008, 28:347-354.
11. Zosmer N., Souter V.L., Chan C.S.Y., et al. Early diagnosis of major cardiac defects in chromosomally normal fetuses with increased nuchal translucency. BJOG 1999, 106:829-833.
12. American College of Obstetricians and Gynecologists (ACOG). Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin No. 77. Washington, DC: American College of Obstetricians and Gynecologists; 2007.
13. Weiner Z., Weizman B., Beloosesky R., et al. Fetal cardiac scanning performed immediately following abnormal nuchal translucency examination. Prenat Diagn 2008, 28:934-938.
14. Maiz N., Plasencia W., Dagklis T., et al. Ductus venosus Doppler in fetuses with cardiac defects and increased nuchal translucency thickness. Ultrasound Obstet Gynecol 2008, 31:256-260.
15. Petrikovsky B.M., Baker D., Schneider E. Fetal hydrops secondary to human parvovirus infection in early pregnancy. Prenat Diagn 1996, 16:342-344.
16. Markenson G., Correia L.A., Cohn G., et al. Parvoviral infection associated with increased nuchal translucency: a case report. J Perinatol 2000, 20:129-131.
17. Smulian J.C., Egan J.F., Rodis J.F. Fetal hydrops in the first trimester associated with maternal parvovirus infection. J Clin Ultrasound 1998, 26:314-316.
18. Sohan K., Carroll S., Byrne D., et al. Parvovirus as a differential diagnosis of hydrops fetalis in the first trimester. Fetal Diagn Ther 2000, 15:234-236.
19. Sebire N.J., Bianco D., Snijders R.J.M., et al. Increased fetal nuchal translucency thickness at 10-14 weeks: is screening for maternal-fetal infection necessary?. BJOG 1997, 104:212-215.
20. Bilardo C.M., Pajkrt E., de Graaf I.M., et al. Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound Obstet Gynecol 1998, 11:401-437.
21. Salvesen D.R., Goble O. Early amniocentesis and fetal nuchal translucency in women requesting karyotyping for advanced maternal age. Prenat Diagn 1995, 15:971-974.
22. Pandya P.P., Kondylios A., Hilbert L., et al. Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 1995, 5:15-19.
23. Ville Y., Lalondrelle C., Doumerc S., et al. First-trimester diagnosis of nuchal anomalies: significance and fetal outcome. Ultrasound Obstet Gynecol 1992, 2:314-316.
24. Nadel A., Bromley B., Benacerraf B.R. Nuchal thickening or cystic hygromas in first- and early second-trimester fetuses: prognosis and outcome. Obstet Gynecol 1993, 82:43-48.
25. Senat M.V., De Keersmaecker B., Audibert F., et al. Pregnancy outcome in fetuses with increased nuchal translucency and normal karyotype. Prenat Diagn 2002, 22:345-349.
26. Markov D., Jacquemyn Y., Leroy Y. Bilateral cleft lip and palate associated with increased nuchal translucency and maternal cocaine abuse at 14 weeks of gestation. Clin Exp Obstet Gynecol 2003, 30:109-110.
27. Van Vugt J.M., Tinnemans B.W., Van Zalen-Sprock R.M. Outcome and early childhood follow-up of chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks' gestation. Ultrasound Obstet Gynecol 1998, 11:407-409.
28. Mangione R., Guyon F., Taine L., et al. Pregnancy outcome and prognosis in fetuses with increased first-trimester nuchal translucency. Fetal Diagn Ther 2001, 16:360-363.
29. Sebire N.J., Snijders R.J.M., Davenport M., et al. Fetal nuchal translucency thickness at 10-14 weeks of gestation and congenital diaphragmatic hernia. Obstet Gynecol 1997, 90:943-947.
30. Varlet F., Bousquet F., Clemenson A., et al. Congenital diaphragmatic hernia. Two cases with early prenatal diagnosis and increased nuchal translucency. Fetal Diagn Ther 2003, 18:33-35.
31. Adekunle O., Gopee A., El-Sayed M., et al. Increased first-trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population. Br J Radiol 1999, 72:457-460.
32. Cha'Ban F.K., van Splunder P., Los F.J., et al. Fetal outcome in nuchal translucency with emphasis on normal fetal karyotype. Prenat Diagn 1996, 16:537-541.
33. Snijders R.J.M., Brizot M.L., Faria M., et al. Fetal exomphalos at 11-14 weeks of gestation. J Ultrasound Med 1995, 14:569-574.
34. van Zalen-Sprock R.M., van Vugt J.M.G., van Geijn H.P. First trimester sonography of physiological midgut herniation and early diagnosis of omphalocele. Prenat Diagn 1997, 17:511-518.
35. Schemm S., Gembruch U., Germer U., et al. Omphalocele-exstrophy-imperforate anus-spinal defects (OEIS) complex associated with increased nuchal translucency. Ultrasound Obstet Gynecol 2003, 22:95-97.
36. Snijders R.J., Sebire N.J., Souka A., et al. Fetal exomphalos and chromosomal defects: relationship to maternal age and gestation. Ultrasound Obstet Gynecol 1995, 6:250-255.
37. Johnson M.P., Johnson A., Holzgreve W., et al. First-trimester simple hygroma: cause and outcome. Am J Obstet Gynecol 1993, 168:156-161.
38. Trauffer M.L., Anderson C.E., Johnson A., et al. The natural history of euploid pregnancies with first trimester cystic hygromas. Am J Obstet Gynecol 1994, 170:1279-1284.
39. Maymon R., Jauniaux E., Cohen O., et al. Pregnancy outcome and infant follow-up of fetuses with abnormally increased first trimester nuchal translucency. Hum Reprod 2000, 15:2023-2027.
40. van Zalen-Sprock R.M., van Vugt J.M.G., van Geijn H.P. First trimester diagnosis of cystic hygroma; course and outcome. Am J Obstet Gynecol 1992, 167:94-98.
41. Sebire N.J., Von Kaisenberg C., Rubio C., et al. Fetal megacystis at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1996, 8:387-390.
42. Favre R., Kohler M., Gasser B., et al. Early fetal megacystis between 11 and 15 weeks of gestation. Ultrasound Obstet Gynecol 1999, 14:402-406.
43. Liao A.W., Sebire N.J., Geerts L., et al. Megacystis at 10-14 weeks of gestation: chromosomal defects and outcome according to bladder length. Ultrasound Obstet Gynecol 2003, 21:338-341.
44. Reynders C.S., Pauker S.P., Benacerraf B.R. First trimester isolated fetal nuchal lucency: significance and outcome. J Ultrasound Med 1997, 16:101-105.
45. Hewitt B. Nuchal translucency in the first trimester. Aust N Z J Obstet Gynaecol 1993, 33:389-391.
46. Fisk N.M., Vaughan J., Smidt M., et al. Transvaginal ultrasound recognition of nuchal oedema in the first-trimester diagnosis of achondrogenesis. J Clin Ultrasound 1991, 19:586-590.
47. Soothill P.W., Vuthiwong C., Rees H. Achondrogenesis type 2 diagnosed by transvaginal ultrasound at 12 weeks of gestation. Prenat Diagn 1993, 13:523-528.
48. Meizner I., Barnhard Y. Achondrogenesis type I diagnosed by transvaginal ultrasonography at 13 weeks' gestation. Am J Obstet Gynecol 1995, 173:1620-1622.
49. Eliyahu S., Weiner E., Lahav D., et al. Early sonographic diagnosis of Jarcho-Levin syndrome: a prospective screening program in one family. Ultrasound Obstet Gynecol 1997, 9:314-318.
50. Lam Y.H., Eik-Nes S.H., Tang M.H.Y., et al. Prenatal sonographic features of spondylocostal dysostosis and diaphragmatic hernia in the first trimester. Ultrasound Obstet Gynecol 1999, 13:213-215.
51. Hull A.D., James G., Pretorius D.H. Detection of Jarcho-Levin syndrome at 12 weeks' gestation by nuchal translucency screening and three-dimensional ultrasound. Prenat Diagn 2001, 21:390-394.
52. Clementschitsch G., Hasenohrl G., Steiner H., et al. Early diagnosis of a fetal skeletal dysplasia associated with increased nuchal translucency with 2D and 3D ultrasound. Ultraschall Med 2003, 24:349-352.
53. Hyett J., Noble P., Sebire N.J., et al. Lethal congenital arthrogryposis presents with increased nuchal translucency at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1997, 9:310-313.
54. Rijhsinghani A., Yankowitz J., Howser D., et al. Sonographic and maternal serum screening abnormalities in fetuses affected by spinal muscular atrophy. Prenat Diagn 1997, 17:166-169.
55. Stiller R.J., Lieberson D., Herzlinger R., et al. The association of increased fetal nuchal translucency and spinal muscular atrophy type I. Prenat Diagn 1999, 19:587-589.
56. de Jong-Pleij E.A., Stoutenbecek P., van der Mark-Batseva N.N., et al. The association of spinal muscular atrophy type II and increased nuchal translucency. Ultrasound Obstet Gynecol 2002, 19:312-313.
57. van Eyndhoven H.W.F., Ter Brugge H.G., van Essen A.J., et al. Beta-glucuronidase deficiency as cause of recurrent hydrops fetalis: the first early prenatal diagnosis by chorionic villus sampling. Prenat Diagn 1998, 18:959-962.
58. den Hollander N.S., Kleijer W.J., Schoonderwaldt E.M., et al. In-utero diagnosis of mucopolysaccharidosis type VII in a fetus with an enlarged nuchal translucency. Ultrasound Obstet Gynecol 2000, 16:87-90.
59. Geipel A., Berg C., Germer U., et al. Mucopolysaccharidosis VII (Sly disease) as a cause of increased nuchal translucency and non-immune fetal hydrops: study of a family and technical approach to prenatal diagnosis in early and late pregnancy. Prenat Diagn 2002, 22:493-495.
60. Hobbins J.C., Jones O.W., Gottesfeld S., et al. Transvaginal sonography and transabdominal embryoscopy in the first-trimester diagnosis of Smith-Lemli-Opitz syndrome, type 2. Am J Obstet Gynecol 1994, 171:546-549.
61. Hyett J.A., Clayton P.T., Moscoso G., et al. Increased first trimester nuchal translucency as a prenatal manifestation of Smith-Lemli-Opitz syndrome. Am J Med Genet 1995, 58:374-376.
62. Sharp P., Haant E., Fletcher J.M., et al. First trimester diagnosis of Smith-Lemli-Opitz syndrome. Prenat Diagn 1997, 17:355-361.
63. de Graaf I.M., Pajkrt E., Keessen M., et al. Enlarged nuchal translucency and low serum protein concentration as possible markers for Zellweger syndrome. Ultrasound Obstet Gynecol 1999, 13:268-270.
64. Christiaens G.C., de Pater J.M., Stoutenbeek P., et al. First trimester nuchal anomalies as a prenatal sign of Zellweger syndrome. Prenat Diagn 2000, 20:517-525.
65. Johnson J.M., Babul-Hirji R., Chitayat D. First-trimester increased nuchal translucency and fetal hypokinesia associated with Zellweger syndrome. Ultrasound Obstet Gynecol 2001, 17:344-346.
66. Cheng C., Bahado-Singh R.O., Chen S., et al. Pregnancy outcomes with increased nuchal translucency after routine Down syndrome screening. Int J Gynaecol Obstet 2004, 84:5-9.
67. Daskalakis G., Sebire N.J., Jurkovic D., et al. Body stalk anomaly at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1997, 10:416-418.
68. Smrcek J.M., Germer U., Krokowski M., et al. Prenatal ultrasound diagnosis and management of body stalk anomaly: analysis of nine singleton and two multiple pregnancies. Ultrasound Obstet Gynecol 2003, 21:322-328.
69. Hiippala A., Eronen M., Taipale P., et al. Fetal nuchal translucency and normal chromosomes: a long-term follow-up study. Ultrasound Obstet Gynecol 2001, 18:18-22.
70. Achiron R., Heggesh J., Grisaru D., et al. Noonan syndrome: a cryptic condition in early gestation. Am J Med Genet 2000, 92:159-165.
71. Bilardo C.M., Muller M.A., Pajkrt E., et al. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 2007, 30:11-18.
72. Brady A.F., Pandya P.P., Yuksel B., et al. Outcome of chromosomally normal live births with increased fetal nuchal translucency at 10-14 weeks' gestation. J Med Genet 1998, 35:222-224.
73. Timor-Tritsch I.E., Fuchs K.M., Monteagudo A., et al. Performing a fetal anatomy scan at the time of first-trimester screening. Obstet Gynecol 2009, 113:402-407.
74. Achiron R., Tadmor O. Screening for fetal anomalies during the first trimester of pregnancy: transvaginal versus transabdominal sonography. Ultrasound Obstet Gynecol 1991, 1:186-191.
75. Carvalho M.H., Brizot M.L., Lopes L.M., et al. Detection of fetal structural abnormalities at the 11-14 week ultrasound scan. Prenat Diagn 2002, 22:1-4.
76. McAuliffe F.M., Fong K.W., Toi A., et al. Ultrasound detection of fetal anomalies in conjunction with first-trimester nuchal translucency screening: a feasibility study. Am J Obstet Gynecol 2005, 193:1260-1265.
77. Drysdale K., Ridley D., Walker K., et al. First trimester pregnancy scanning as a screening tool for high-risk and abnormal pregnancies in a district general hospital setting. J Obstet Gynaecol 2002, 22:159-165.
78. Cafici D., Sepulveda W. First-trimester echogenic amniotic fluid in the acrania-anencephaly sequence. J Ultrasound Med 2003, 22:1075-1079.
79. Ong C.Y.T., Liao A.W., Spencer K., et al. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000, 107:1265-1270.
80. Goetzl L., Krantz D., Simpson J.L., et al. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 2004, 104:30-36.
81. Dugoff L., Cuckle H.S., Hobbins J.C., et al. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers. Am J Obstet Gynecol 2008, 199:290. e1-6.
82. Brameld K.J., Dickinson J.E., O'Leary P., et al. First trimester predictors of adverse pregnancy outcomes. Aust N Z J Obstet Gynaecol 2008, 48:529-535.
83. Scott F., Coates A., McLennan A. Pregnancy outcome in the setting of extremely low first trimester PAPP-A levels. Aust N Z J Obstet Gynaecol 2009, 49:258-262.
84. Smith G.C., Crossley J.A., Aitken D.A., et al. First-trimester placentation and the risk of antepartum stillbirth. JAMA 2004, 292:2249-2254.
85. Smith G.C., Stenhouse E.J., Crossley J.A., et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002, 87:1762-1767.
86. Spencer K., Cowans N.J., Avgidou K., et al. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2008, 31:15-19.
87. Krantz D., Goetzl L., Simpson J.L., First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group, et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004, 191:1452-1458.
88. Spencer K., Cowans N.J., Molina F., et al. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol 2008, 31:147-152.
89. Smith G.C., Shah I., Crossley J.A., et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol 2006, 107:161-166.
90. Fox N.S., Shalom D., Chasen S.T. Second-trimester fetal growth as a predictor of poor obstetric and neonatal outcome in patients with low first-trimester serum pregnancy-associated plasma protein-A and a euploid fetus. Ultrasound Obstet Gynecol 2009, 33:34-38.
91. Cooper S., Johnson J.A., Metcalfe A., et al. The predictive value of 18 and 22 week uterine artery Doppler in patients with low first trimester maternal serum PAPP-A. Prenat Diagn 2009, 29:248-252.
92. Poon L.C., Zaragoza E., Akolekar R., et al. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008, 28:1110-1115.
93. Spencer K., Yu C.K., Cowans N.J., et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005, 25:949-953.
94. Poon L.C., Maiz N., Valencia C., et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009, 33:23-33.
95. Akolekar R., Minekawa R., Veduta A., et al. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 2009, 29:753-760.
96. Nicolaides K.H., Bindra R., Turan O.M., et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006, 27:13-17.
97. Poon L.C., Kametas N.A., Maiz N., et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009, 53:812-818.
98. Hoffman J.D., Bianchi D.W., Sullivan L.M., et al. Down syndrome serum screening also identifies an increased risk for multicystic dysplastic kidney, two-vessel cord, and hydrocele. Prenat Diagn 2008, 28:1204-1208.
99. Uccella S., Colombo G.F., Bulgheroni C.M., et al. First-trimester maternal serum screening and the risk for fetal distress during labor. Am J Obstet Gynecol 2009, 201(2):166. e1-6.